Skip to content
Peptigraph home

CagriSema Phase 2 trial (NCT04982575)

Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
92
actual
Start
2 Aug 2021 (actual)
Primary completion
7 Jul 2022 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT04982575 study arms
ArmTypeInterventionsDescription
Cagrilintide 2.4 mg and semaglutide 2.4 mgExperimentalDrug: Semaglutide 2.4 mg; Drug: Cagrilintide 2.4 mgParticipants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
Cagrilintide 2.4 mg and placebo (semaglutide)Active comparatorDrug: Cagrilintide 2.4 mg; Drug: Placebo (semaglutide)Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
Semaglutide 2.4 mg and Placebo (cagrilintide)Active comparatorDrug: Semaglutide 2.4 mg; Drug: Placebo (cagrilintide)Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
Endpoints

Primary endpoint

NCT04982575 primary outcomes
MeasureTime frame
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)Week 0, Week 32
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04982575 secondary outcomes
MeasureTime frame
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)Week 0, Week 32
Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)Week 0, Week 32
Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)Week 0, Week 32
Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)Week 0, Week 32
CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)Week 0, Week 32
Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)At week 32
Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)At week 32
Number of Treatment Emergent Adverse Events (TEAEs)From baseline (week 0) to week 37
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)From baseline (week 0) to week 37
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04982575.

How the CagriSema type 2 diabetes comparison was set up

This 32-week trial across 17 US sites randomised adults with type 2 diabetes 1:1:1 to CagriSema, semaglutide or cagrilintide, each escalated to 2.4 mg.[2]

Change in HbA1c from baseline was the primary endpoint, with bodyweight, fasting glucose, CGM measures and safety as secondary endpoints.[2]

Glycaemic, weight and safety results at week 32

HbA1c fell by 2.2 points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide, and the CagriSema edge held against cagrilintide (p<0.0001) but not semaglutide (p=0.075).[2]

Bodyweight changed by -15.6% with CagriSema, -5.1% with semaglutide and -8.1% with cagrilintide.[2]

CGM time in range rose to 88.9%, 76.2% and 71.7% in the three arms respectively.[2]

Adverse events were reported by 68%, 71% and 80% of participants in the CagriSema, semaglutide and cagrilintide groups, mostly mild or moderate gastrointestinal events.[2]

Sources

  1. 1Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026

Found an error? Report a correction.